{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:06:01Z","timestamp":1789383961216,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40487-026-00446-7","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:27:44Z","timestamp":1780662464000},"page":"967-981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine Learning-Guided Survival Prediction and Treatment Sequencing in Advanced Soft Tissue Sarcoma Beyond Second-Line Therapy: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Michael","family":"Hoberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Di Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy L.","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"V\u00f6lkl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan E.","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vindi","family":"Jurinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Albertsmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Roland","family":"D\u00fcrr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt\u2013Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kn\u00f6sel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt\u2013Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Burkhard\u2013Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-138X","authenticated-orcid":false,"given":"Luc M.","family":"Berclaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"1","key":"446_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R De Angelis","year":"2014","unstructured":"De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE-5\u2014a population-based study. Lancet Oncol. 2014;15(1):23\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(13)70546-1.","journal-title":"Lancet Oncol"},{"issue":"12","key":"446_CR2","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1634\/theoncologist.2016-0474","volume":"22","author":"A Comandone","year":"2016","unstructured":"Comandone A, Petrelli F, Boglione A, Barni S. Salvage therapy in advanced adult soft tissue sarcoma: a systematic review and meta-analysis of randomized trials. Oncologist. 2016;22(12):1518\u201327. https:\/\/doi.org\/10.1634\/theoncologist.2016-0474.","journal-title":"Oncologist"},{"issue":"9829","key":"446_CR3","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT Van Der Graaf","year":"2012","unstructured":"Van Der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(12)60651-5.","journal-title":"Lancet"},{"issue":"19","key":"446_CR4","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer\u2013Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol. 2009;27(19):3126\u201332. https:\/\/doi.org\/10.1200\/JCO.2008.21.3223.","journal-title":"J Clin Oncol"},{"issue":"3","key":"446_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ijc.21867","volume":"119","author":"J Bay","year":"2006","unstructured":"Bay J, Ray\u2010Coquard I, Fayette J, et al. Docetaxel and Gemcitabine combination in 133 advanced soft\u2010tissue sarcomas: a retrospective analysis. Int J Cancer. 2006;119(3):706\u201311. https:\/\/doi.org\/10.1002\/ijc.21867.","journal-title":"Int J Cancer"},{"issue":"1","key":"446_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4143\/crt.2016.535","volume":"50","author":"Y Choi","year":"2018","unstructured":"Choi Y, Yun MS, Lim SH,et al. Gemcitabine and docetaxel combination for advanced soft tissue sarcoma: a nationwide retrospective study. Cancer Res Treat. 2018;50(1):175\u201382. https:\/\/doi.org\/10.4143\/crt.2016.535.","journal-title":"Cancer Res Treat"},{"issue":"19","key":"446_CR7","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","volume":"25","author":"RG Maki","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of Gemcitabine and Docetaxel compared with Gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol. 2007;25(19):2755\u201363. https:\/\/doi.org\/10.1200\/JCO.2006.10.4117.","journal-title":"J Clin Oncol"},{"issue":"6","key":"446_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.33216","volume":"127","author":"N Somaiah","year":"2021","unstructured":"Somaiah N, Van Tine BA, Wahlquist AE, et al. A randomized, open\u2010label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft\u2010tissue sarcoma. Cancer. 2021;127(6):894\u2013904. https:\/\/doi.org\/10.1002\/cncr.33216.","journal-title":"Cancer"},{"issue":"25","key":"446_CR9","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Chawla SP, Von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and Ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188\u201396. https:\/\/doi.org\/10.1200\/JCO.2008.21.0088.","journal-title":"J Clin Oncol"},{"issue":"5","key":"446_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","volume":"22","author":"A Yovine","year":"2004","unstructured":"Yovine A, Riofrio M, Blay JY, et al. Phase II study of Ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22(5):890\u20139. https:\/\/doi.org\/10.1200\/JCO.2004.05.210.","journal-title":"J Clin Oncol"},{"issue":"3","key":"446_CR11","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","volume":"23","author":"A Le Cesne","year":"2005","unstructured":"Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European organisation for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trial. JCO. 2005;23(3):576\u201384. https:\/\/doi.org\/10.1200\/JCO.2005.01.180.","journal-title":"JCO"},{"issue":"1","key":"446_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-64","volume":"13","author":"JY Blay","year":"2013","unstructured":"Blay JY, Italiano A, Ray-Coquard I, et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with Trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer. 2013;13(1):64. https:\/\/doi.org\/10.1186\/1471-2407-13-64.","journal-title":"BMC Cancer"},{"issue":"8","key":"446_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1634\/theoncologist.2016-0064","volume":"22","author":"M Takahashi","year":"2017","unstructured":"Takahashi M, Takahashi S, Araki N, et al. Efficacy of Trabectedin in patients with advanced translocation-related sarcomas: pooled analysis of two phase II studies. Oncologist. 2017;22(8):979\u201388. https:\/\/doi.org\/10.1634\/theoncologist.2016-0064.","journal-title":"Oncologist"},{"issue":"2","key":"446_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10637-007-9086-z","volume":"26","author":"PA Zucali","year":"2008","unstructured":"Zucali PA, Bertuzzi A, Parra HJS, Campagnoli E, Quagliuolo V, Santoro A. The \u201cold drug\u201d Dacarbazine as a second\/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs. 2008;26(2):175\u201381. https:\/\/doi.org\/10.1007\/s10637-007-9086-z.","journal-title":"Invest New Drugs"},{"issue":"8","key":"446_CR15","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/cncr.21384","volume":"104","author":"X Garcia Del Muro","year":"2005","unstructured":"Garcia Del Muro X, Lopez\u2010Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6\u2010week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer. 2005;104(8):1706\u201312. https:\/\/doi.org\/10.1002\/cncr.21384.","journal-title":"Cancer"},{"issue":"1","key":"446_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/SRCM\/2006\/15947","volume":"2006","author":"SE Anderson","year":"2006","unstructured":"Anderson SE, Keohan ML, D\u2032Adamo DR, Maki RG. A retrospective analysis of Vinorelbine chemotherapy for patients with previously treated soft\u2010tissue sarcomas. Sarcoma. 2006;2006(1):015947. https:\/\/doi.org\/10.1155\/SRCM\/2006\/15947.","journal-title":"Sarcoma"},{"issue":"10028","key":"446_CR17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Sch\u00f6ffski","year":"2016","unstructured":"Sch\u00f6ffski P, Chawla S, Maki RG, et al. Eribulin versus Dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(15)01283-0.","journal-title":"Lancet"},{"issue":"12","key":"446_CR18","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1007\/s12094-023-03221-6","volume":"25","author":"L Gutierrez-Sainz","year":"2023","unstructured":"Gutierrez-Sainz L, Martinez-Fdez S, Pedregosa-Barbas J, et al. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study. Clin Transl Oncol. 2023;25(12):3519\u201326. https:\/\/doi.org\/10.1007\/s12094-023-03221-6.","journal-title":"Clin Transl Oncol"},{"key":"446_CR19","volume-title":"The elements of statistical learning: data mining, inference, and prediction","author":"T Hastie","year":"2017","unstructured":"Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning: data mining, inference, and prediction. 2nd ed. New York: Springer; 2017.","edition":"2"},{"issue":"10","key":"446_CR20","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1093\/annonc\/mds070","volume":"23","author":"M Leahy","year":"2012","unstructured":"Leahy M, Garcia Del Muro X, Reichardt P, et al. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and burden of illness in North America and Europe (SABINE) study. Ann Oncol. 2012;23(10):2763\u201370. https:\/\/doi.org\/10.1093\/annonc\/mds070.","journal-title":"Ann Oncol"},{"issue":"5","key":"446_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","volume":"17","author":"D Callegaro","year":"2016","unstructured":"Callegaro D, Miceli R, Bonvalot S, F, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(16)00010-3.","journal-title":"Lancet Oncol"},{"key":"446_CR22","unstructured":"Lehmann EL, Romano JP. Testing statistical hypotheses. 3rd ed. New York: Springer; 2008."},{"issue":"7","key":"446_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12325-016-0344-3","volume":"33","author":"EM Gordon","year":"2016","unstructured":"Gordon EM, Sankhala KK, Chawla N, Chawla SP. Trabectedin for soft tissue sarcoma: current status and future perspectives. Adv Ther. 2016;33(7):1055\u201371. https:\/\/doi.org\/10.1007\/s12325-016-0344-3.","journal-title":"Adv Ther"},{"issue":"4","key":"446_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","volume":"77","author":"AK Larsen","year":"2016","unstructured":"Larsen AK, Galmarini CM, D\u2019Incalci M. Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol. 2016;77(4):663\u201371. https:\/\/doi.org\/10.1007\/s00280-015-2918-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"446_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/14737140.2020.1822744","volume":"20","author":"LM de Sande Gonz\u00e1lez","year":"2020","unstructured":"de Sande Gonz\u00e1lez LM, Martin-Broto J, Kasper B, Blay JY, Le Cesne A. Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. Expert Rev Anticancer Ther. 2020;20(11):957\u201363. https:\/\/doi.org\/10.1080\/14737140.2020.1822744.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"446_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103995","volume":"9","author":"B Vincenzi","year":"2024","unstructured":"Vincenzi B, Olimpieri PP, Celant S, et al. Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry. ESMO Open. 2024;9(12):103995. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103995.","journal-title":"ESMO Open"},{"issue":"1","key":"446_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5988-3","volume":"19","author":"AL Cesne","year":"2019","unstructured":"Cesne AL, Bauer S, Demetri GD, et al. Safety and efficacy of pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer. 2019;19(1):794. https:\/\/doi.org\/10.1186\/s12885-019-5988-3.","journal-title":"BMC Cancer"},{"issue":"3","key":"446_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajco.14138","volume":"21","author":"I Wilson","year":"2025","unstructured":"Wilson I, Strach M, Bhadri V, Harrison M, Tang W, Grimison P. Real-world outcomes of patients treated with gemcitabine using standardized dose and rate and docetaxel for advanced soft tissue sarcoma in an Australian sarcoma center. Asia Pac J Clin Oncol. 2025;21(3):305\u201310. https:\/\/doi.org\/10.1111\/ajco.14138.","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00446-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00446-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00446-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:32:14Z","timestamp":1789381934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00446-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00446-7","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Hoberger, Dorit Di Gioia, Romy L Zuber, Michael V\u00f6lkl, Sinan E G\u00fcler, Vindi Jurinovic, Markus Albertsmeier, Alexander Klein, Hans Roland D\u00fcrr, Nina-Sophie Schmidt\u2013Hegemann, Thomas Kn\u00f6sel, Wolfgang G Kunz, Michael von Bergwelt\u2013Baildon, Lars H Lindner, Anton Burkhard\u2013Meier, and Luc M Berclaz have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by the Internal Review Board and the Ethical Review Committee of the LMU Hospital Munich, Germany (Protocol No. 26-0142).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}